What will 2020 bring for medicine and science? We asked 16 leaders for predictions
Last year, when we asked science and health care soothsayers to peek ahead to 2019, they told us that methamphetamine use would rise (it did), tumor organoids would near clinical use for personalizing cancer treatment and better targeting clinical trials (that’s happening), and price transparency wouldn’t bring lower health spending (that’s true, too). But nobody predicted the outbreak of lung injuries tied to vaping, the failure and attempted resurrection of Biogen’s Alzheimer’s drug aducanumab, or the restoration of cellular functions in pig brains after death.
We’re back with a new set of predictions for 2020. Let’s see how our experts do this time.
Results for a broad array of approaches to treating Alzheimer’s
Alzheimer’s research and discovery is moving quickly, from possible early detection to treatments — which could be a combination approach: mixes of medicines, or drug and lifestyle combos, that attack the disease from multiple angles. Thanks to increased funding and exploration of new ideas, scientists now know more about dementia than ever before, and are investigating a diverse array of options.
Looking to 2020, the scientific community eagerly awaits the FDA’s review of Biogen’s amyloid-attacking drug, aducanumab. We’re also anticipating results from studies of anti-tau compounds, strategies to reduce brain inflammation, research into oral microbes and gut bacteria, dementia prevention trials, and developments in early detection such as biomarkers. Finally, research looking at lifestyle-related contributions to dementia risk continues to advance, including clinical trials such as U.S. POINTER.
— Maria C. Carrillo, chief science officer, Alzheimer’s Association
Read more:
